BOLTBolt Biotherapeutics, Inc.Signing up patients
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
Gastric Cancer Adenocarcinoma Metastatic · Gastroesophageal Adenocarcinoma
6Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +5.7
3 insiders sold shares within a month
Since Sep 18, 2026 · was worth 10, fading over time
Worry score6
Score over time
- Stage
- Phase 1/2
- Patients
- 122 (planned)
- Started
- May 26, 2025
- Main results expected
- May 2027
- Fully finished
- May 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of adverse events (AEs) and serious adverse events (SAEs) graded according to CTCAE v5.0
Measured over: approximately 2 years
Incidence and nature of AEs considered by the Investigator or Sponsor to be clinically relevant, attributable to study treatment, and meeting dose-limiting toxicity (DLT) criteria
Measured over: Up to 21 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 5.7, since 2026-09-18, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06921837 · record last updated 2026-01-27 · checked 2026-11-09 15:47 UTC